Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

LYV Chart
LYV data by YCharts

Live Nation Entertainment (LYV - Get Report) : In an exclusive interview, Cramer sat down with Michael Rapino, president and CEO of Live Nation, the live music production company with 158 venues in six countries as well as four of the top five music festivals in the U.S.

Rapino said that Live Nation is all about the live concert side of the business. He said his company now has a complete ecosystem that provides everything from ticket sales to food and beverages and even live streaming of shows to drive digital advertising dollars. In a world where artists make 90% of their income from playing live, Live Nation is becoming increasingly important.

Rapino continued by noting that Live Nation will produce over 25,000 shows this year, including 66 music festivals around the globe. Thanks to technology, artists are becoming known worldwide, he said, leaving Live Nation with lots of room still to grow.

Live Nation is both a business-to-business company, attracting artists and venues, but also a business-to-consumer company, thanks to its acquisition of TicketMaster. Rapino said they now have the ability to know their customers even better and offer more personalized services.

ONCE Chart
ONCE data by YCharts

Spark Therapeutics (ONCE - Get Report) : In his second interview segment, Cramer also sat down with Jeff Marrazzo, co-founder and CEO at Spark Therapeutics, a development-stage biotech company working on gene therapies to cure some rare genetic diseases.

Marrazzo explained that gene therapy aims to correct the underlying causes of certain diseases by delivering the necessary genes to patients that need then.

Spark's first drug, which targets the RPE65 gene that causes blindness in some children, is thus far showing miraculous results. Marrazzo said that RPE65 is one of over 200 genes that can cause blindness, which makes his company hopeful that their therapy can be applied to other genes as well.

When asked about the explosion in gene therapy treatments, Marrazzo said the growth is two-fold. First, there is better genetic testing available to discover and understand which genes are in play and second, there are new technologies available to attack the problem genes.

Spark is also exploring treatments for hemophilia and other diseases. Cramer said this company is capable of amazing things.

AMBA Chart
AMBA data by YCharts

Ambarella (AMBA - Get Report) , Fitbit (FIT - Get Report) and GoPro (GPRO - Get Report) : Are these three stocks simply too expensive to own? Cramer took a closer look and said not necessarily.

When factoring in these companies' growth rates and their market potential, all three are not as expensive as they seem, Cramer noted, which is why he's be a buyer of any one of them during the next market pullback.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.